Medco Health Solutions — Accredo Health — Merger or Acquisition (February 2005)
22 slides from Medco Health Solutions's merger presentation, Feb 23, 2005

Slide 1: Filed by Medco Health Solutions pursuant to Rule 425
Filed by Medco Health Solutions, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Accredo Health, Incorporated Subject Company’s Exchange Act File No.: 0-25769

Slide 2: Medco Health Solutions / Accredo Health Investor Presentation, February 23, 2005
Medco Health Accredo Investor February Presentation Health, 23, 2005 Solutions, Incorporated Inc.

Slide 3: Forward-Looking Statements
Forward This amended future could integrating result effects rules, 2 conference we cause of financial onuncertainty looking by have future the actual theposted businesses and Private call results, statements results operating surrounding and this Securities performance webcast to of document, diffe

Slide 4: Key Transaction Terms
Keyshare Per Consideration Transaction Conditions Timing: 3 transaction Mid-2005 consideration: tostructure: value: closing: mix: terms $2.2 $22Tax-free Accredo billion cash Valueand equivalent equity reorganization, stockholder .49107 value; shares toapproval $43.33 $2.4 excluding ofbillion Medco p

Slide 5: Acquisition Creates Largest Specialty Pharmacy Company
Acquisition Specialty For ($ Medco $ *Combined $700 Source: 4 3,500 745 millions) the +12 $2,600 Wall Company Caremark Revenues months creates revenue $4,500 Street $1,700 Reports ended largest $4,000 Equity Medco excludes 12/2004 and specialty Research $3,500 Accredo dual-counted Wall$3,000 Street

Slide 6: Specialty Drugs: Fastest Growing Share of Drug Spend
Specialty Annual New Source: 5 drugs costs Jefferies drug pharmacies in of development spend treatments & Company is provide fastest $8,000—$200,000 – potentially therapies Research—January growing for share expanding chronic, of total 26, overall life-threatening drug 2005;spend market May $22+ 26,

Slide 7: Specialty Drug Trend at Medco
Specialty Medco Trend Utilization Mix Net 5.1% (Inflation, Drug Source: 6 Pricing (0.6%) Trend 2.9% Driver book Medco pharmacy discounts, 15.9% 20.4% 0.2% of Specialty Data business 5.4% 8.5% growing co-pays) Drugs experience 20%+ All Drugs FY 2004

Slide 8: Nearly 400 Biotechnology Medicines in Development
Nearly Therapeutic Infectious Genetic Number 1 2 3 5 9 10 11 14 16 17 19 26 43 *Some Source: 7 7 100 medicines Pharmaceutical disorders ofdiseases Products products Category Skin are Autoimmune inlisted disorders Development* biotechnology Research in more disorders Eye and than conditions Manufactu

Slide 9: Accredo: A Leading Pure-Play Specialty Pharmacy Company
Accredo A Medications third-party Therapeutic 6 Other, Respiratory Gaucher Growth Pulmonary Multiple Hemophilia 8 months leading 12% Hormone Disease, company Sclerosis, ending pure-play payors Arterial Syncytial A/1 Mix provided &12/31/04 6% Disorders, overview Primary 16% Hypertension, specialty Vi

Slide 10: Accredo Operates Under Three Brands
Accredo Six One Fourteen 9 product product operates product lines line Hybrid Local lines underCentralized dispensing three dispensing brands Physician dispensing HTC, DTC &Manufacturer MC & MC sales sales Hands sales Nurse/Pharmacist onPharmacist nursing Highest team teamLow High service service se

Slide 11: Accredo Pharmacy and Distribution Locations
Accredo Seattle Pittsburgh Jacksonville Hemophilia Kansas New Primary Memphis Satellite 10 Orleans San City office pharmacy distribution (2) Francisco Health (2) Nashville Houston Newark Washington, Dallas/Ft. Services capabilities Ft. Los Greensboro Pittsburgh Lauderdale Angeles Worth DC Greensboro

Slide 12: Acquisition Builds Upon Medco's Specialty Pharmacy Offering
Acquisition Medco (MM 11.6 29.3 Feb 576 Growth Cancer Anemia Over Source: 11 Jul clients 6.5 125 ofSpecialty Jan Medco Hormone Infertility lives 1.7 drugs representing Jun builds 0.2 covered) data Jan covering Pharmacy Hemophilia MS upon 2003 Pulmonary 29.3 Medco’s 23 2003 therapeutic MM Hepatitis 2

Slide 13: Combination Leverages Strengths of Each Entity
Combination Broad Medco Dispensing Limited Accredo 12 access access Automation leverages Reimbursement strengths Access to Technology ofPayors each entity & Access PatientstoClient Physicians Solutions Manufacturer Scale Solutions Niche Focus

Slide 14: Complementary Fit and Significant Up-sell Opportunity
Complementary Significant Up-sell Enhance Builds 13 on Medco critical existing, cross-selling drugs products reimbursement highly to Accredo opportunity and successful services expertise patients relationship Up-sell and clinical Medcosupport specialty Earlydrugs involvement to Accredo with clients

Slide 15: Enhanced Distribution Provider Status for Specialty Drugs
Enhanced Distribution Provider Adagen Actimmune Aldurazyme Apokyn Aralast Clotting Cerezyme Botox Avonex Fabrazyme Enbrel Flolan Growth Orfadin IVIG Prolastin Remodulin Raptiva Synagis Tracleer Zavesca Xolair Zemaira Source: 14 restricted restricted SEC Hormone exclusive restricted exclusive Factor

Slide 16: Attractive Financial Characteristics and Continued Growth
Attractive Internal Continued Enhances 15 growth future financial growth rates growth ofcharacteristics and Medco opportunities margins specialty at attractive businesslevels —potential Upsidetopotential expand into due additional to robust pipeline disease of states new biotech drugs requiring spec

Slide 17: Overview of Expected Financial Benefits and Synergies
Overview Top Over 16 line $40growth million of expected opportunity, in expected financial high annual benefits margin pre-tax business synergies, Expected with atomajority be accretive coming to Medco throughinoperational 2006, excluding leverage onetime and cross-selling merger related opportuniti

Slide 18: Selected Pro Forma Financial Information
Selected For ended (unaudited) $35.4 EBITDA Net Medco 12/25/04 Debt/EBITDA Debt/Total 17 the Revenue Income BN 12/25/04 Proposed twelve information Pro $1.2 $1.7 Capitalization Medco $481.6 Forma BN months 0.78 BN ended Capitalization $154.6 Accredo MM x2004 1.45 12/31/04 For $76.1 15 MM xthe%twelve

Slide 19: Transaction Summary
Transaction Robust Specialty platform, Strong 18 financial pipeline customer patients summary of profile, also new service use specialty expected traditional and client products to bebase medications accretive and additional inand near benefit term indications from integration will continue Accelera

Slide 20: Medco Health Solutions, Inc.
Health, Incorporated” =

Slide 21: Additional Information
Additional In Exchange obtain (http://www.sec.gov).These Medco Investor site, Medco, stockholders stockholders, stockholders. when 20 connection www.accredohealth.net, they free Health Accredo Relations Commission become Information copies in Additional dated with Solutions, respect and of Departmen

Slide 22: Use of Non-GAAP Measures
Usechanges net supplemental not accepted must calculation EBITDA per-unit by Medco connection these 21 income, represent ofbe intangibles Non-GAAP calculates uses considered basis, accounting per of with in and earnings adjusted funds measurement EBITDA prescription providing cash the isand aMeasure
Source: SEC EDGAR · 425 filed Feb 23, 2005
More decks from Medco Health Solutions Inc
Merger or Acquisition (July 2011)20 slides · Jul 22, 2011
Sanford C. Bernstein 27th Annual Strategic Decisions Conference 201125 slides · Jun 1, 2011
Deutsche Bank 36th Annual Health Care Conference 201130 slides · May 3, 2011
Investor Presentation (March 2011)36 slides · Mar 24, 2011
Barclays Capital 2011 Global Health Care Conference36 slides · Mar 17, 2011
Citi 2011 Global Health Care Conference37 slides · Mar 1, 2011